RxDoctor Payments DataLook up a doctor →

Ziad Abbud, MD

Interventional Cardiology · Ocean, NJNPI 1740373489

Payments from drug & device makers

$360,728in general payments, 2019–2025

Across 1,493 payments — averaging $241.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$154K
  • Esperion Therapeutics, Inc.$82K
  • AstraZeneca$55K
  • Cardiovascular Systems Inc.$31K
  • Novartis$11K
  • Lilly USA, LLC$7K
  • plus $21K from 51 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim230$153,749
Esperion Therapeutics, Inc.111$82,491
AstraZeneca128$55,444
Cardiovascular Systems Inc.120$30,752
Novartis107$10,593
Lilly USA, LLC9$6,973
Novo Nordisk44$4,998
Abbott179$3,153
Biotronik Inc.88$2,158
Medtronic(2 entities)16$1,190
Amgen76$1,094
Abiomed13$988
Johnson & Johnson45$760
Kestra Medical Technology Services, Inc.9$591
Sanofi-aventis U.S. LLC39$546
Arbor Pharmaceuticals, Inc.58$541
Boston Scientific24$423
Cardinal Health 200 LLC26$398
Merck21$373
Astellas Pharma US Inc7$346
Bard Peripheral Vascular, Inc.3$283
Alnylam Pharmaceuticals Inc.7$234
Philips North America LLC4$207
Scpharmaceuticals Inc.11$201
Irhythm Technologies, Inc.8$200
Kowa Pharmaceuticals America, Inc.11$161
Pfizer9$143
Cordis US CORP.9$139
Inari Medical, Inc.1$118
Bayer7$115
Angiodynamics, Inc.3$113
Lexicon Pharmaceuticals, Inc.7$112
Regeneron Healthcare Solutions, Inc.7$103
Heartflow, Inc.4$103
Saranas, Inc.2$92
Daiichi Sankyo Inc.6$80
GSK4$71
Lundbeck LLC5$70
Cvrx, Inc.4$60
Amryt Pharma Holdings Ltd3$50
Impulse Dynamics (USA) Inc.2$49
Azurity Pharmaceuticals, Inc.3$47
Kiniksa Pharmaceuticals, Ltd.3$47
Akcea Therapeutics, Inc.3$44
Biosense Webster, Inc.1$38
Atricure, Inc.2$36
Kiniksa Pharmaceuticals International, PLC2$35
Bridgebio Pharma, Inc.2$35
Baxter Healthcare1$31
E.r. Squibb & Sons, L.L.C.2$28
Biocompatibles, Inc.1$24
Teleflex LLC1$20
Bardy Diagnostics, Inc.1$20
Edwards Lifesciences1$19
Cleerly, Inc.1$17
EMD Serono, Inc.1$15
Chiesi USA, Inc.1$12

How this compares

$360,728 in reported general payments places this provider in the 95th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey →

Medicare billing

Part B allowed, 2024
$2,007,759
Medicare patients
1,930
Services billed
14,987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Ocean

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →